Arcus Biosciences RCUS
NYSE RCUS
$29.58 -0.55 (-1.83%)
As of: Sep 4, 2026 · 2:25 PM EDT

Arcus Biosciences (RCUS) EV to EBITDA (2018 - 2026)

Analysis

Arcus Biosciences (RCUS) EV to EBITDA (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.87 Bn 131.01 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.57 Bn 77.57 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.19 Bn 53.05 Bn 52.00 Mn
5 Revolution Medicines 44.07 Bn 44.07 Bn -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.38 Bn 32.07 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn
10 Arcus Biosciences 3.73 Bn 3.03 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -33.47
Mar 31, 2026 -14.10
Dec 31, 2025 -17.59
Sep 30, 2025 -4.41
Jun 30, 2025 5.61
Mar 31, 2025 1.36
Dec 31, 2024 -3.83
Sep 30, 2024 -2.95
Jun 30, 2024 -3.98
Mar 31, 2024 -45.07
Dec 31, 2023 -7.51
Sep 30, 2023 -6.80
Jun 30, 2023 -7.03
Mar 31, 2023 -4.41
Dec 31, 2022 -6.74
Sep 30, 2022 -12.05
Jun 30, 2022 -9.47
Mar 31, 2022 -15.62
Dec 31, 2021 8.42
Sep 30, 2021 -24.63